Abstract:Ovarian cancer is the number one cause of death from gynecologic malignancy. A defective p53 pathway is a hallmark of ovarian carcinoma. The p53 mutation correlates significantly with resistance to platinum-based chemotherapy, early relapse and shortened overall survival in ovarian cancer patients. PUMA (p53 upregulated modulator of apoptosis), a BH3-only Bcl-2 family protein, was recently identified as a transcriptional target of p53 and a potent apoptosis inducer in various cancer cells. In this study, we showed that the induction of PUMA by cisplatin was abolished in p53-deficient SKOV3 cells. Elevated expression of PUMA-induced apoptosis and sensitized A2780s and SKOV3 ovarian cancer cells to cisplatin, and the combination of PUMA and low-dose cisplatin, significantly suppressed xenograft tumor growth in vivo through enhanced induction of apoptosis compared with treatment with PUMA or cisplatin alone. The effects of PUMA were mediated by enhanced caspase activation and release of cytochrome c and Smac (second mitochondria-derived activator of caspase) into the cytosol. Furthermore, PUMA chemosensitized intrinsically resistant SKOV3 cells to cisplatin through downregulation of B-cell lymphoma-extra large (Bcl-x(L)) and myeloid cell leukemia sequence 1 (Mcl-1). PUMA-mediated Bcl-x(L) downregulation mainly happened at the transcription level, whereas PUMA-induced Mcl-1 down-regulation was associated with caspase-dependent cleavage and proteasome-mediated degradation. To our knowledge, these data suggest a new mechanism by which overexpression of PUMA enhances sensitivity of SKOV3 cells to cisplatin by lowering the threshold set simultaneously by Bcl-x(L) and Mcl-1. Taken together, our findings indicate that PUMA is an important modulator of therapeutic responses of ovarian cancer cells and is potentially useful as a chemosensitizer in ovarian cancer therapy.

The Role of PUMA in Oxaliplatin-Induced Apoptosis in Colon Cancer Cells

The BH3-only Protein, PUMA, is Involved in Oxaliplatin-Induced Apoptosis in Colon Cancer Cells

Polyunsaturated Fatty Acids Trigger Apoptosis of Colon Cancer Cells Through a Mitochondrial Pathway.

Jnk- And Akt-Mediated Puma Expression In The Apoptosis Of Cisplatin-Resistant Ovarian Cancer Cells

The role of ROS and subsequent DNA-damage response in PUMA-induced apoptosis of ovarian cancer cells.

The Expression of PUMA in Colon Carcinoma Cells and Its Effect in Cell Apoptosis

Effects of Exogenous PUMA on Proliferation and Apoptosis of Non-Small Cell Lung Cancer A549 Cells

The P53 Upregulated Modulator of Apoptosis (PUMA) Chemosensitizes Intrinsically Resistant Ovarian Cancer Cells to Cisplatin by Lowering the Threshold Set by Bcl-x(L) and Mcl-1.

Effects of tetramethylpyrazine on proliferation and apoptosis in human colon cancer cells and its mechanism

Puma Overexpression Induces Reactive Oxygen Species Generation And Proteasome-Mediated Stathmin Degradation In Colorectal Cancer Cells

Regulation of PUMA- α by p53 in cisplatin-induced renal cell apoptosis

Combination of Hydroxycamptothecine with Oxaliplatin in Induction of Drug-Resistant Colorectal Cancer Cell Line LoVo/5-FU and Mechanism of Apoptosis

Sp1 is Involved in H2O2-induced PUMA Gene Expression and Apoptosis in Colorectal Cancer Cells

Exogenous P53 Upregulated Modulator of Apoptosis (PUMA) Decreases Growth of Lung Cancer A549 Cells

The BH3-only protein PUMA is involved in green tea polyphenol-induced apoptosis in colorectal cancer cell lines

PUMA mediates the combinational therapy of 5-FU and NVP-BEZ235 in colon cancer.

Figure S5 from PUMA/RIP3 Mediates Chemotherapy Response via Necroptosis and Local Immune Activation in Colorectal Cancer

Targeting Mtor Suppressed Colon Cancer Growth Through 4ebp1/eif4e/puma Pathway

Mechanism of Taurine-Induced Apoptosis in Human Colon Cancer Cells

PUMA Overexpression Dissociates Thioredoxin from ASK1 to Activate the JNK/BCL-2/BCL-XL Pathway Augmenting Apoptosis in Ovarian Cancer.

Pro-apoptotic Function of PUMA in Human Tumor